Evidence map›Paper›PMID 28011809›Full record

Trial reportBMJ open2016

Safety and efficacy of tocotrienol supplementation for bone health in postmenopausal women: protocol for a dose-response double-blinded placebo-controlled randomised trial.

Chwan-Li Shen, Huanbiao Mo, Shengping Yang, Shu Wang, Carol K Felton, Michael D Tomison, Ima Nirwana Soelaiman

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMJ open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02058420 (Effect of Tocotrienols on Bone Health), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02058420 phase1 / phase2completednot on this map

Effect of Tocotrienols on Bone Health: A Pilot Study

TypeinterventionalSponsorTexas Tech University Health Sciences CenterRan2014 to 2022Enrolled78ConditionsOsteoporosisArmsLow tocotrienols group, High tocotrienols group
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Chwan-Li ShenDepartment of Pathology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Huanbiao MoDepartment of Nutrition, Byrdine F. Lewis School of Nursing and Health Professions, Georgia State University, Atlanta, Georgia, USA.
Shengping YangDepartment of Pathology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Shu WangDepartment of Nutritional Sciences, Texas Tech University, Lubbock, Texas, USA.
Carol K FeltonDepartment of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Michael D TomisonDepartment of Pathology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Ima Nirwana SoelaimanDepartment of Pharmacology, Universiti Kebangasaan Malaysia, Kuala Lumpur, Malaysia.
Texas Tech University · USTexas Tech University Health Sciences Center · USGeorgia State University · USNational University of Malaysia · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOsteoporosis is a major health concern in postmenopausal women, and oxidative stress contributes to the development of bone loss. Cellular studies and ovariectomised rat model mimicking bone loss in postmenopausal women show the bone-protective effect of tocotrienols (TTs) with antioxidant capability. We aim to access the safety and efficacy of TT consumption for bone health in postmenopausal women. METHODS AND ANALYSIS: In this 12-week randomised double-blinded placebo-controlled trial for the effects of dietary TT supplementation in postmenopausal women, postmenopausal women aged 45 years and older with at least 1 year after menopause and bone mineral density T-score at the spine and/or hip 2.5 or more below the reference values will be randomly assigned to 3 daily supplements: (1) placebo group receiving 860 mg olive oil, (2) low TT group receiving 430 mg of 70% pure TTs (containing 300 mg TT) and (3) high TT group receiving 860 mg of 70% pure TTs (600 mg TT). The primary outcome measure will be urinary N-terminal telopeptide. The secondary outcome measures will be serum bone-specific alkaline phosphatase, receptor activator of nuclear factor-κB ligand, osteoprotegerin, urinary 8-hydroxy-2'-deoxyguanosine and quality of life. At 0, 6 and 12 weeks, the following will be assessed: (1) primary and secondary outcome measures; (2) serum TT and tocopherol concentrations; (3) physical activity and food frequency questionnaires. Liver function will be monitored every 6 weeks for safety. 'Intent-to-treat' principle will be employed for data analysis. A model of repeated measurements with random effect error terms will be applied. Analysis of covariance, χ ETHICS AND DISSEMINATION: This study was approved by the Bioethics Committee of the Texas Tech University Health Sciences Center. The findings of this trial will be submitted to a peer-reviewed journal in the areas of bone or nutrition and international conferences. TRIAL REGISTRATION NUMBER: NCT02058420; results.

Indexed as

Dietary SupplementsAgedAged, 80 and overAntioxidantsBiomarkersBone and BonesBone DensityDose-Response Relationship, DrugFemaleHumansLiverMiddle AgedOsteoporosis, PostmenopausalPostmenopauseResearch DesignTocotrienolsAntioxidantsBiomarkersTocotrienolsbone turnover markerintervention trialosteoporosisoxidative stresstocotrienolswomen

Identifiers

PMID28011809
PMCPMC5223723
OpenAlexW2564087512

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.